Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Sep 15;102(6):1142–1151. doi: 10.1172/JCI3492

LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer.

Y Zhai 1, R Guo 1, T L Hsu 1, G L Yu 1, J Ni 1, B S Kwon 1, G W Jiang 1, J Lu 1, J Tan 1, M Ugustus 1, K Carter 1, L Rojas 1, F Zhu 1, C Lincoln 1, G Endress 1, L Xing 1, S Wang 1, K O Oh 1, R Gentz 1, S Ruben 1, M E Lippman 1, S L Hsieh 1, D Yang 1
PMCID: PMC509097  PMID: 9739048

Abstract

LIGHT is a new member of tumor necrosis factor (TNF) cytokine family derived from an activated T cell cDNA library. LIGHT mRNA is highly expressed in splenocytes, activated PBL, CD8(+) tumor infiltrating lymphocytes, granulocytes, and monocytes but not in the thymus and the tumor cells examined. Introduction of LIGHT cDNA into MDA-MB-231 human breast carcinoma caused complete tumor suppression in vivo. Histological examination showed marked neutrophil infiltration and necrosis in LIGHT expressing but not in the parental or the Neo-transfected MDA-MB-231 tumors. Interferon gamma (IFNgamma) dramatically enhances LIGHT-mediated apoptosis. LIGHT protein triggers apoptosis of various tumor cells expressing both lymphotoxin beta receptor (LTbetaR) and TR2/HVEM receptors, and its cytotoxicity can be blocked specifically by addition of a LTbetaR-Fc or a TR2/HVEM-Fc fusion protein. However, LIGHT was not cytolytic to the tumor cells that express only the LTbetaR or the TR2/HVEM or hematopoietic cells examined that express only the TR2/HVEM, such as PBL, Jurkat cells, or CD8(+) TIL cells. In contrast, treatment of the activated PBL with LIGHT resulted in release of IFNgamma. Our data suggest that LIGHT triggers distinct biological responses based on the expression patterns of its receptors on the target cells. Thus, LIGHT may play a role in the immune modulation and have a potential value in cancer therapy.

Full Text

The Full Text of this article is available as a PDF (412.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams M. D., Kerlavage A. R., Fleischmann R. D., Fuldner R. A., Bult C. J., Lee N. H., Kirkness E. F., Weinstock K. G., Gocayne J. D., White O. Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence. Nature. 1995 Sep 28;377(6547 Suppl):3–174. [PubMed] [Google Scholar]
  2. Aggarwal B. B., Natarajan K. Tumor necrosis factors: developments during the last decade. Eur Cytokine Netw. 1996 Apr-Jun;7(2):93–124. [PubMed] [Google Scholar]
  3. Baker S. J., Reddy E. P. Transducers of life and death: TNF receptor superfamily and associated proteins. Oncogene. 1996 Jan 4;12(1):1–9. [PubMed] [Google Scholar]
  4. Browning J. L., Miatkowski K., Sizing I., Griffiths D., Zafari M., Benjamin C. D., Meier W., Mackay F. Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines. J Exp Med. 1996 Mar 1;183(3):867–878. doi: 10.1084/jem.183.3.867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Browning J. L., Ngam-ek A., Lawton P., DeMarinis J., Tizard R., Chow E. P., Hession C., O'Brine-Greco B., Foley S. F., Ware C. F. Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell. 1993 Mar 26;72(6):847–856. doi: 10.1016/0092-8674(93)90574-a. [DOI] [PubMed] [Google Scholar]
  6. Chinnaiyan A. M., Dixit V. M. Portrait of an executioner: the molecular mechanism of FAS/APO-1-induced apoptosis. Semin Immunol. 1997 Feb;9(1):69–76. doi: 10.1006/smim.1996.0055. [DOI] [PubMed] [Google Scholar]
  7. Chinnaiyan A. M., O'Rourke K., Yu G. L., Lyons R. H., Garg M., Duan D. R., Xing L., Gentz R., Ni J., Dixit V. M. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science. 1996 Nov 8;274(5289):990–992. doi: 10.1126/science.274.5289.990. [DOI] [PubMed] [Google Scholar]
  8. Crowe P. D., VanArsdale T. L., Walter B. N., Ware C. F., Hession C., Ehrenfels B., Browning J. L., Din W. S., Goodwin R. G., Smith C. A. A lymphotoxin-beta-specific receptor. Science. 1994 Apr 29;264(5159):707–710. doi: 10.1126/science.8171323. [DOI] [PubMed] [Google Scholar]
  9. Degli-Esposti M. A., Davis-Smith T., Din W. S., Smolak P. J., Goodwin R. G., Smith C. A. Activation of the lymphotoxin beta receptor by cross-linking induces chemokine production and growth arrest in A375 melanoma cells. J Immunol. 1997 Feb 15;158(4):1756–1762. [PubMed] [Google Scholar]
  10. Depraetere V., Golstein P. Fas and other cell death signaling pathways. Semin Immunol. 1997 Apr;9(2):93–107. doi: 10.1006/smim.1997.0062. [DOI] [PubMed] [Google Scholar]
  11. Hsu H., Solovyev I., Colombero A., Elliott R., Kelley M., Boyle W. J. ATAR, a novel tumor necrosis factor receptor family member, signals through TRAF2 and TRAF5. J Biol Chem. 1997 May 23;272(21):13471–13474. doi: 10.1074/jbc.272.21.13471. [DOI] [PubMed] [Google Scholar]
  12. Hurtado J. C., Kim Y. J., Kwon B. S. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J Immunol. 1997 Mar 15;158(6):2600–2609. [PubMed] [Google Scholar]
  13. Johnson C. V., McNeil J. A., Carter K. C., Lawrence J. B. A simple, rapid technique for precise mapping of multiple sequences in two colors using a single optical filter set. Genet Anal Tech Appl. 1991 Apr;8(2):75–76. doi: 10.1016/1050-3862(91)90052-s. [DOI] [PubMed] [Google Scholar]
  14. Johnson C. V., Singer R. H., Lawrence J. B. Fluorescent detection of nuclear RNA and DNA: implications for genome organization. Methods Cell Biol. 1991;35:73–99. [PubMed] [Google Scholar]
  15. Kwon B. S., Tan K. B., Ni J., Oh K. O., Lee Z. H., Kim K. K., Kim Y. J., Wang S., Gentz R., Yu G. L. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem. 1997 May 30;272(22):14272–14276. doi: 10.1074/jbc.272.22.14272. [DOI] [PubMed] [Google Scholar]
  16. Markowitz D., Goff S., Bank A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol. 1988 Apr;62(4):1120–1124. doi: 10.1128/jvi.62.4.1120-1124.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Marsters S. A., Ayres T. M., Skubatch M., Gray C. L., Rothe M., Ashkenazi A. Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. J Biol Chem. 1997 May 30;272(22):14029–14032. doi: 10.1074/jbc.272.22.14029. [DOI] [PubMed] [Google Scholar]
  18. Mauri D. N., Ebner R., Montgomery R. I., Kochel K. D., Cheung T. C., Yu G. L., Ruben S., Murphy M., Eisenberg R. J., Cohen G. H. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity. 1998 Jan;8(1):21–30. doi: 10.1016/s1074-7613(00)80455-0. [DOI] [PubMed] [Google Scholar]
  19. Montgomery R. I., Warner M. S., Lum B. J., Spear P. G. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell. 1996 Nov 1;87(3):427–436. doi: 10.1016/s0092-8674(00)81363-x. [DOI] [PubMed] [Google Scholar]
  20. Mueller H., Flury N., Liu R., Scheidegger S., Eppenberger U. Tumour necrosis factor and interferon are selectively cytostatic in vitro for hormone-dependent and hormone-independent human breast cancer cells. Eur J Cancer. 1996 Dec;32A(13):2312–2318. doi: 10.1016/s0959-8049(96)00273-0. [DOI] [PubMed] [Google Scholar]
  21. Pan G., Ni J., Wei Y. F., Yu G., Gentz R., Dixit V. M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 1997 Aug 8;277(5327):815–818. doi: 10.1126/science.277.5327.815. [DOI] [PubMed] [Google Scholar]
  22. Pan G., O'Rourke K., Chinnaiyan A. M., Gentz R., Ebner R., Ni J., Dixit V. M. The receptor for the cytotoxic ligand TRAIL. Science. 1997 Apr 4;276(5309):111–113. doi: 10.1126/science.276.5309.111. [DOI] [PubMed] [Google Scholar]
  23. Pitti R. M., Marsters S. A., Ruppert S., Donahue C. J., Moore A., Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996 May 31;271(22):12687–12690. doi: 10.1074/jbc.271.22.12687. [DOI] [PubMed] [Google Scholar]
  24. Sheridan J. P., Marsters S. A., Pitti R. M., Gurney A., Skubatch M., Baldwin D., Ramakrishnan L., Gray C. L., Baker K., Wood W. I. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997 Aug 8;277(5327):818–821. doi: 10.1126/science.277.5327.818. [DOI] [PubMed] [Google Scholar]
  25. Simonet W. S., Lacey D. L., Dunstan C. R., Kelley M., Chang M. S., Lüthy R., Nguyen H. Q., Wooden S., Bennett L., Boone T. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997 Apr 18;89(2):309–319. doi: 10.1016/s0092-8674(00)80209-3. [DOI] [PubMed] [Google Scholar]
  26. Smith C. A., Farrah T., Goodwin R. G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 1994 Mar 25;76(6):959–962. doi: 10.1016/0092-8674(94)90372-7. [DOI] [PubMed] [Google Scholar]
  27. Tewari M., Dixit V. M. Recent advances in tumor necrosis factor and CD40 signaling. Curr Opin Genet Dev. 1996 Feb;6(1):39–44. doi: 10.1016/s0959-437x(96)90008-8. [DOI] [PubMed] [Google Scholar]
  28. VanArsdale T. L., VanArsdale S. L., Force W. R., Walter B. N., Mosialos G., Kieff E., Reed J. C., Ware C. F. Lymphotoxin-beta receptor signaling complex: role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor kappaB. Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2460–2465. doi: 10.1073/pnas.94.6.2460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Wiley S. R., Schooley K., Smolak P. J., Din W. S., Huang C. P., Nicholl J. K., Sutherland G. R., Smith T. D., Rauch C., Smith C. A. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995 Dec;3(6):673–682. doi: 10.1016/1074-7613(95)90057-8. [DOI] [PubMed] [Google Scholar]
  30. Zhai Y., Yang J. C., Kawakami Y., Spiess P., Wadsworth S. C., Cardoza L. M., Couture L. A., Smith A. E., Rosenberg S. A. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J Immunol. 1996 Jan 15;156(2):700–710. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES